Rebecca Taub
2020
In 2020, Rebecca Taub earned a total compensation of $3.9M as President, Research &Development and Chief Medical Officer at Synta Pharmaceuticals, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $339,230 |
|---|---|
| Option Awards | $3,052,280 |
| Salary | $490,833 |
| Total | $3,882,343 |
Taub received $3.1M in option awards, accounting for 79% of the total pay in 2020.
Taub also received $339.2K in non-equity incentive plan and $490.8K in salary.
Rankings
In 2020, Rebecca Taub's compensation ranked 2,949th out of 13,090 executives tracked by ExecPay. In other words, Taub earned more than 77.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,949 out of 13,090 | 78th |
Division Manufacturing | 1,144 out of 5,617 | 80th |
Major group Chemicals And Allied Products | 425 out of 2,248 | 81st |
Industry group Drugs | 368 out of 1,948 | 81st |
Industry Pharmaceutical Preparations | 271 out of 1,453 | 81st |
Source: SEC filing on May 2, 2022.
Taub's colleagues
We found four more compensation records of executives who worked with Rebecca Taub at Synta Pharmaceuticals in 2020.